{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:31:14Z","timestamp":1794241874230,"version":"4.9.0"},"posted":{"date-parts":[[2026,8,13]]},"group-title":"In Review","reference-count":52,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,7,17]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  <bold>Background:<\/bold>\n                  Donor lymphocyte infusion (DLI) is used to prevent and treat leukemic relapse after allogeneic hematopoietic cell transplantation, although its efficacy against lymphoid malignancies remains limited. Blinatumomab (Blina), a CD3\/CD19 bispecific T-cell engager, is increasingly used to enhance DLI activity against acute lymphoblastic leukemia (ALL). We previously demonstrated that exercise-mobilized DLI (DLI-X) exhibits superior anti-leukemic activity against myeloid malignancies. Here, we investigated whether DLI-X combined with Blina enhances cytotoxicity against CD19\u207a B-ALL.\n                  <bold\/>\n                  <bold>Methods:<\/bold>\n                  Peripheral blood mononuclear cells (PBMCs) were collected from healthy participants at rest (DLI) and during the final stage of a 20-minute graded cycling protocol to 80% VO\u2082max (DLI-X). Cytotoxicity against CD19\u207a RS4;11 B-ALL cells was assessed in vitro. T-cell activation and effector function were evaluated by 8-color flow cytometry. In vivo efficacy was determined in NSG-IL-15 mice engrafted with RS4;11 cells and treated with DLI or DLI-X in combination with Blina or vehicle, with tumor burden monitored by bioluminescence imaging.\n                  <bold\/>\n                  <bold>Results:<\/bold>\n                  DLI and DLI-X alone exhibited limited cytotoxicity against RS4;11 cells. Blina significantly enhanced cytotoxicity of both products, with DLI-X+Blina demonstrating &gt;20% greater tumor killing than DLI+Blina (~85% vs. ~62%). Compared with DLI, DLI-X displayed enhanced Blina-induced T-cell effector function, including increased CD107a degranulation, greater TNF-\u03b1 production by CD4\u207a T cells, higher IFN-\u03b3 production by CD8\u207a T cells, and 10\u201315% greater upregulation of CD137 and OX40. In vivo, DLI-X+Blina achieved up to 35% greater control of tumor burden than DLI+Blina.\n                  <bold>Conclusions:<\/bold>\n                  Exercise mobilizes T cells with enhanced responsiveness to Blina, resulting in superior activation and cytotoxicity against CD19\u207a B-ALL cells in vitro and improved tumor control in vivo. These findings support the use of exercise-mobilized DLI as a strategy to enhance the efficacy of bispecific T-cell engager therapy following allogeneic hematopoietic cell transplantation.\n                  <bold\/>\n                  <bold>Trial registration:<\/bold>\n                  ClinicalTrials.gov, NCT06643221. Registered retrospectively on October 8, 2024.\n                <\/p>","DOI":"10.21203\/rs.3.rs-10395685\/v1","type":"posted-content","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T02:04:37Z","timestamp":1786586677000},"source":"Crossref","is-referenced-by-count":0,"title":["Exercise-Mobilized Donor Lymphocytes Enhance Blinatumomab Activity Against B-ALL"],"prefix":"10.21203","author":[{"given":"John L","family":"Sullivan","sequence":"first","affiliation":[{"name":"The University of Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geovana","family":"Leite","sequence":"additional","affiliation":[{"name":"The University of Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina Santa","family":"Cruz","sequence":"additional","affiliation":[{"name":"The University of Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Batatinha","sequence":"additional","affiliation":[{"name":"The University of Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin A","family":"Swanson","sequence":"additional","affiliation":[{"name":"The University of Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Filioglou","sequence":"additional","affiliation":[{"name":"The University of Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace M","family":"McKenzie","sequence":"additional","affiliation":[{"name":"The University of Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M","family":"Kistner","sequence":"additional","affiliation":[{"name":"The University of Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhu S","family":"Arunachalam","sequence":"additional","affiliation":[{"name":"The University of Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forrest L","family":"Baker","sequence":"additional","affiliation":[{"name":"University of South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Katsanis","sequence":"additional","affiliation":[{"name":"The University of Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7064-6881","authenticated-orcid":false,"given":"Richard","family":"Simpson","sequence":"additional","affiliation":[{"name":"The University of Arizona College of Medicine \u2013 Tucson: The University of Arizona College of Medicine Tucson"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Donor lymphocyte infusion as immune modulation after pediatric allogeneic transplantation","author":"Filioglou D","unstructured":"Filioglou D, Simpson RJ, Katsanis E. Donor lymphocyte infusion as immune modulation after pediatric allogeneic transplantation. Blood Immunol Cell Ther 2026;In press.","journal-title":"Blood Immunol Cell Ther"},{"issue":"7","key":"ref2","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.bbmt.2015.03.012","article-title":"Donor lymphocyte infusions for chronic myeloid leukemia relapsing after allogeneic stem cell transplantation: may we predict graft-versus-leukemia without graft-versus-host disease?","volume":"21","author":"Radujkovic A","year":"2015","unstructured":"Radujkovic A, Guglielmi C, Bergantini S, et al. Donor lymphocyte infusions for chronic myeloid leukemia relapsing after allogeneic stem cell transplantation: may we predict graft-versus-leukemia without graft-versus-host disease? Biol Blood Marrow Transpl. 2015;21(7):1230\u20136.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3324\/haematol.2019.219790","article-title":"Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT","volume":"105","author":"Dholaria B","year":"2020","unstructured":"Dholaria B, Savani BN, Labopin M, et al. Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. Haematologica. 2020;105(1):47\u201358.","journal-title":"Haematologica"},{"issue":"7","key":"ref4","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.bbmt.2013.04.014","article-title":"Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation","volume":"19","author":"Poon LM","year":"2013","unstructured":"Poon LM, Hamdi A, Saliba R, et al. Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2013;19(7):1059\u201364.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"15","key":"ref5","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.3390\/cancers13153886","article-title":"Why do children with acute lymphoblastic leukemia fare better than adults?","volume":"13","author":"Neaga A","year":"2021","unstructured":"Neaga A, Jimbu L, Mesaros O, Bota M, Lazar D, Zdrenghea M. Why do children with acute lymphoblastic leukemia fare better than adults? Cancers (Basel). 2021;13(15):3886.","journal-title":"Cancers (Basel)"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"20406207221099468","DOI":"10.1177\/20406207221099468","article-title":"Relapsed acute lymphoblastic leukaemia after allogeneic stem cell transplantation: a therapeutic dilemma challenging the armamentarium of immunotherapies currently available (case reports)","volume":"13","author":"Poyer F","year":"2022","unstructured":"Poyer F, F\u00fcreder A, Holter W, Peters C, Boztug H, Dworzak M, Engstler G, Friesenbichler W, K\u00f6hrer S, L\u00fcftinger R, Ronceray L, Witt V, Pichler H, Attarbaschi A. Relapsed acute lymphoblastic leukaemia after allogeneic stem cell transplantation: a therapeutic dilemma challenging the armamentarium of immunotherapies currently available (case reports). Ther Adv Hematol. 2022;13:20406207221099468.","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp MS","year":"2015","unstructured":"Topp MS, Gokbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57\u201366.","journal-title":"Lancet Oncol"},{"issue":"9","key":"ref8","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1177\/1060028015588555","article-title":"Blinatumomab: a first-in-class bispecific T-cell engager for precursor B-cell acute lymphoblastic leukemia","volume":"49","author":"Buie LW","year":"2015","unstructured":"Buie LW, Pecoraro JJ, Horvat TZ, Daley RJ. Blinatumomab: a first-in-class bispecific T-cell engager for precursor B-cell acute lymphoblastic leukemia. Ann Pharmacother. 2015;49(9):1057\u201367.","journal-title":"Ann Pharmacother"},{"issue":"5","key":"ref9","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3109\/10428194.2016.1161185","article-title":"Blinatumomab: a CD19\/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy","volume":"57","author":"Goebeler ME","year":"2016","unstructured":"Goebeler ME, Bargou R. Blinatumomab: a CD19\/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. Leuk Lymphoma. 2016;57(5):1021\u201332.","journal-title":"Leuk Lymphoma"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41409-024-02475-0","article-title":"The BLIND study: blinatumomab and DLI approach for management of B-ALL relapse after allogeneic stem cell transplantation. A multicentric Italian experience","volume":"60","author":"Giammarco S","year":"2025","unstructured":"Giammarco S, De Ritis A, Pagliaro A, et al. The BLIND study: blinatumomab and DLI approach for management of B-ALL relapse after allogeneic stem cell transplantation. A multicentric Italian experience. Bone Marrow Transpl. 2025;60:396\u20139.","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00277-021-04731-5","article-title":"Donor lymphocyte infusion after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia","volume":"101","author":"Harada K","year":"2022","unstructured":"Harada K, Mizuno S, Yano S, et al. Donor lymphocyte infusion after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia. Ann Hematol. 2022;101(3):643\u201353.","journal-title":"Ann Hematol"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1159\/000531834","article-title":"Combination of donor lymphocyte infusion and blinatumomab for B-cell lymphoblastic lymphoma relapse after allogeneic stem-cell transplantation","volume":"16","author":"Mori Y","year":"2023","unstructured":"Mori Y, Sasaki K, Ito Y, et al. Combination of donor lymphocyte infusion and blinatumomab for B-cell lymphoblastic lymphoma relapse after allogeneic stem-cell transplantation. Case Rep Oncol. 2023;16(1):640\u20134.","journal-title":"Case Rep Oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2040620721994348","article-title":"Concurrent application of blinatumomab and haploidentical donor leukocyte infusions for refractory primary mediastinal large B-cell lymphoma","volume":"12","author":"Smith J","year":"2021","unstructured":"Smith J, Kumar A, Stanton NA, Katsanis E. Concurrent application of blinatumomab and haploidentical donor leukocyte infusions for refractory primary mediastinal large B-cell lymphoma. Ther Adv Hematol. 2021;12:1\u20136.","journal-title":"Ther Adv Hematol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1563972","DOI":"10.3389\/fimmu.2025.1563972","article-title":"Exercise-mobilized donor lymphocyte infusions enhanced with cytokine stimulation for the prevention and treatment of leukemic relapse after allogeneic hematopoietic cell transplantation","volume":"16","author":"McDougal LM","year":"2025","unstructured":"McDougal LM, Valenzuela AM, Baker FL, Simpson RJ. Exercise-mobilized donor lymphocyte infusions enhanced with cytokine stimulation for the prevention and treatment of leukemic relapse after allogeneic hematopoietic cell transplantation. Front Immunol. 2025;16:1563972.","journal-title":"Front Immunol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.bbi.2018.08.017","article-title":"\u03b22-Adrenergic receptor signaling mediates the preferential mobilization of differentiated subsets of CD8\u2009+\u2009T-cells, NK-cells and non-classical monocytes in response to acute exercise in humans","volume":"74","author":"Graff RM","year":"2018","unstructured":"Graff RM, Kunz HE, Agha NH, et al. \u03b22-Adrenergic receptor signaling mediates the preferential mobilization of differentiated subsets of CD8\u2009+\u2009T-cells, NK-cells and non-classical monocytes in response to acute exercise in humans. Brain Behav Immun. 2018;74:143\u201353.","journal-title":"Brain Behav Immun"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bbi.2013.10.030","article-title":"Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells","volume":"39","author":"Bigley AB","year":"2014","unstructured":"Bigley AB, Rezvani K, Chew C, et al. Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells. Brain Behav Immun. 2014;39:160\u201371.","journal-title":"Brain Behav Immun"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.bbi.2021.07.010","article-title":"Exercise and adrenergic regulation of immunity","volume":"97","author":"Simpson RJ","year":"2021","unstructured":"Simpson RJ, Bo\u00dflau TK, Weyh C, Niemiro GM, et al. Exercise and adrenergic regulation of immunity. Brain Behav Immun. 2021;97:303\u201318.","journal-title":"Brain Behav Immun"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1067369","DOI":"10.3389\/fimmu.2023.1067369","article-title":"Human lymphocytes mobilized with exercise have an anti-tumor transcriptomic profile and exert enhanced graft-versus-leukemia effects in xenogeneic mice","volume":"14","author":"Batatinha H","year":"2023","unstructured":"Batatinha H, Diak DM, Niemiro GM, et al. Human lymphocytes mobilized with exercise have an anti-tumor transcriptomic profile and exert enhanced graft-versus-leukemia effects in xenogeneic mice. Front Immunol. 2023;14:1067369.","journal-title":"Front Immunol"},{"issue":"17","key":"ref19","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.3390\/cancers17172826","article-title":"Exercise delays human leukemia progression and mitigates graft-versus-host disease after donor lymphocyte infusion in xenogeneic mice","volume":"17","author":"Batatinha H","year":"2025","unstructured":"Batatinha H, Pe\u00f1a NA, Hoskin GA, Kistner TM, Diak DM, Niemiro GM, Katsanis E, Simpson RJ. Exercise delays human leukemia progression and mitigates graft-versus-host disease after donor lymphocyte infusion in xenogeneic mice. Cancers (Basel). 2025;17(17):2826.","journal-title":"Cancers (Basel)"},{"key":"ref20","volume-title":"ACSM's Guidelines for Exercise Testing and Prescription","year":"2025","unstructured":"Ozemek C, Bonikowske A, Christle J, Gallo P, editors. ACSM's Guidelines for Exercise Testing and Prescription. 12th ed. Wolters Kluwer Health; 2025.","edition":"12"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41409-024-02458-1","article-title":"Utility of the 2024 best practice recommendations from the EBMT Cellular Therapy and Immunobiology Working Party for use of donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation","volume":"60","author":"Mamez AC","year":"2025","unstructured":"Mamez AC, Pradier A, Morin S, et al. Utility of the 2024 best practice recommendations from the EBMT Cellular Therapy and Immunobiology Working Party for use of donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl. 2025;60:247\u20139.","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"ref22","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41590-020-0758-6","article-title":"The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation","volume":"21","author":"Ng SS","year":"2020","unstructured":"Ng SS, De Labastida Rivera F, Yan J, et al. The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation. Nat Immunol. 2020;21(10):1205\u201318.","journal-title":"Nat Immunol"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1158\/2326-6066.CIR-21-0539","article-title":"NKG7 is a T-cell-intrinsic therapeutic target for improving antitumor cytotoxicity and cancer immunotherapy","volume":"10","author":"Wen T","year":"2022","unstructured":"Wen T, Barham W, Li Y, et al. NKG7 is a T-cell-intrinsic therapeutic target for improving antitumor cytotoxicity and cancer immunotherapy. Cancer Immunol Res. 2022;10(2):162\u201381.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1182\/blood-2007-08-109678","article-title":"Effector memory CD4\u2009+\u2009T cells mediate graft-versus-leukemia without inducing graft-versus-host disease","volume":"111","author":"Zheng H","year":"2008","unstructured":"Zheng H, Matte-Martone C, Li H, et al. Effector memory CD4\u2009+\u2009T cells mediate graft-versus-leukemia without inducing graft-versus-host disease. Blood. 2008;111(4):2476\u201384.","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"893545","DOI":"10.3389\/fimmu.2022.893545","article-title":"Naive T cells in graft versus host disease and graft versus leukemia: innocent or guilty?","volume":"13","author":"Dekker L","year":"2022","unstructured":"Dekker L, Sanders E, Lindemans CA, de Koning C, Nierkens S. Naive T cells in graft versus host disease and graft versus leukemia: innocent or guilty? Front Immunol. 2022;13:893545.","journal-title":"Front Immunol"},{"issue":"4","key":"ref26","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.hemonc.2017.05.006","article-title":"Memory T cells: a helpful guard for allogeneic hematopoietic stem cell transplantation without causing graft-versus-host disease","volume":"10","author":"Huang W","year":"2017","unstructured":"Huang W, Chao NJ. Memory T cells: a helpful guard for allogeneic hematopoietic stem cell transplantation without causing graft-versus-host disease. Hematol Oncol Stem Cell Ther. 2017;10(4):211\u20139.","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41409-022-01846-9","article-title":"Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC","volume":"58","author":"Chauvet P","year":"2023","unstructured":"Chauvet P, Paviglianiti A, Labopin M, Labussi\u00e8re H, Boissel N, Robin M, Maillard N, Ouach\u00e9e-Chardin M, Forcade E, Poir\u00e9 X, Chantepie S, Huynh A, Bulabois CE, Leclerc M, Maury S, Chevallier P, Cluzeau T, Mear JB, Cornillon J, Bilger K, Simand C, Beguin Y, Rubio MT, Yakoub-Agha I, Brissot E. Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC. Bone Marrow Transpl. 2023;58(1):72\u20139.","journal-title":"Bone Marrow Transpl"},{"issue":"10230","key":"ref28","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard F","year":"2020","unstructured":"Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020;395(10230):1146\u201362.","journal-title":"Lancet"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1191912","DOI":"10.3389\/fimmu.2023.1191912","article-title":"Novel strategies to prevent and overcome relapse after allogeneic hematopoietic cell transplantation in acute lymphoblastic leukemia","volume":"14","author":"Hodroj MH","year":"2023","unstructured":"Hodroj MH, Abou Dalle I, Moukalled N, El Cheikh J, Mohty M, Bazarbachi A. Novel strategies to prevent and overcome relapse after allogeneic hematopoietic cell transplantation in acute lymphoblastic leukemia. Front Immunol. 2023;14:1191912.","journal-title":"Front Immunol"},{"issue":"4","key":"ref30","first-page":"1285","article-title":"Relapsed\/refractory acute lymphoblastic leukemia post-allogeneic transplant: current and emerging treatment strategies","volume":"15","author":"Varadarajan I","year":"2023","unstructured":"Varadarajan I, Wu HH, Ballen KK. Relapsed\/refractory acute lymphoblastic leukemia post-allogeneic transplant: current and emerging treatment strategies. Cancers (Basel). 2023;15(4):1285.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"ref31","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(24)00098-X","article-title":"Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT","volume":"11","author":"Pagliuca S","year":"2024","unstructured":"Pagliuca S, Labopin M, Blaise D, et al. Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT. Lancet Haematol. 2024;11(6):e448\u201358.","journal-title":"Lancet Haematol"},{"key":"ref32","article-title":"Exercise-mobilized lymphocytes enhance antibody-based immunotherapy in multiple myeloma through CD16\u2009+\u2009NK cell-mediated cytotoxicity","author":"Chou L","unstructured":"Chou L, Valenzuela AM, McDougal LM, Baker FL, Simpson RJ. Exercise-mobilized lymphocytes enhance antibody-based immunotherapy in multiple myeloma through CD16\u2009+\u2009NK cell-mediated cytotoxicity. J Transl Med 2026;In press.","journal-title":"J Transl Med"},{"key":"ref33","author":"Leite G","year":"2026","unstructured":"Leite G, Sullivan J, Filioglou D, Kounelis M, Batatinha H, Simpson R, Katsanis E. Blinatumomab bypasses CD28 blockade to sustain T-cell cytotoxicity and improve survival in a xenograft B-ALL model. J Immunother Cancer. 2026;In press."},{"issue":"9","key":"ref34","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/bmt.2016.104","article-title":"Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoietic cell transplant","volume":"51","author":"Ueda M","year":"2016","unstructured":"Ueda M, de Lima M, Caimi P, et al. Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoietic cell transplant. Bone Marrow Transpl. 2016;51(9):1253\u20135.","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"ref35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2217\/imt-2018-0104","article-title":"Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature review","volume":"11","author":"Durer S","year":"2019","unstructured":"Durer S, Durer C, Shafqat M, et al. Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature review. Immunotherapy. 2019;11(5):373\u20138.","journal-title":"Immunotherapy"},{"issue":"2","key":"ref36","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1097\/MPH.0000000000001789","article-title":"Combination therapy with chemotherapy, donor lymphocyte infusion with concurrent blinatumomab in relapsed\/refractory acute precursor B-lymphoblastic leukemia","volume":"43","author":"Choi G","year":"2021","unstructured":"Choi G, Shin JH, Cho BS, et al. Combination therapy with chemotherapy, donor lymphocyte infusion with concurrent blinatumomab in relapsed\/refractory acute precursor B-lymphoblastic leukemia. J Pediatr Hematol Oncol. 2021;43(2):e198\u2013202.","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1345884","DOI":"10.3389\/frhem.2024.1345884","article-title":"Case report: donor lymphocyte infusion and blinatumomab as treatment for acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation","volume":"3","author":"Cacace F","year":"2024","unstructured":"Cacace F, Vitiello S, Muriano F, et al. Case report: donor lymphocyte infusion and blinatumomab as treatment for acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation. Front Hematol. 2024;3:1345884.","journal-title":"Front Hematol"},{"issue":"9","key":"ref38","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian H","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Fo\u00e0 R, Bassan R, Arslan \u00d6, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Br\u00fcggemann M, Klapper W, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836\u201347.","journal-title":"N Engl J Med"},{"issue":"1","key":"ref39","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1152\/japplphysiol.00007.2007","article-title":"High-intensity exercise elicits the mobilization of senescent T lymphocytes into the peripheral blood compartment in human subjects","volume":"103","author":"Simpson RJ","year":"2007","unstructured":"Simpson RJ, Florida-James GD, Cosgrove C, et al. High-intensity exercise elicits the mobilization of senescent T lymphocytes into the peripheral blood compartment in human subjects. J Appl Physiol. 2007;103(1):396\u2013401.","journal-title":"J Appl Physiol"},{"issue":"6","key":"ref40","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.bbi.2009.02.011","article-title":"Acute exercise mobilises CD8\u2009+\u2009T lymphocytes exhibiting an effector-memory phenotype","volume":"23","author":"Campbell JP","year":"2009","unstructured":"Campbell JP, Riddell NE, Burns VE, Turner M, van Zanten JJCSV, Drayson MT, Bosch JA. Acute exercise mobilises CD8\u2009+\u2009T lymphocytes exhibiting an effector-memory phenotype. Brain Behav Immun. 2009;23(6):767\u201375.","journal-title":"Brain Behav Immun"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"938106","DOI":"10.3389\/fimmu.2022.938106","article-title":"Acute exercise mobilizes NKT-like cells with a cytotoxic transcriptomic profile but does not augment the potency of cytokine-induced killer (CIK) cells","volume":"13","author":"Z\u00fa\u00f1iga TM","year":"2022","unstructured":"Z\u00fa\u00f1iga TM, Baker FL, McGill JK, et al. Acute exercise mobilizes NKT-like cells with a cytotoxic transcriptomic profile but does not augment the potency of cytokine-induced killer (CIK) cells. Front Immunol. 2022;13:938106.","journal-title":"Front Immunol"},{"issue":"7","key":"ref42","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.molmed.2016.05.007","article-title":"Exercise-dependent regulation of NK cells in cancer protection","volume":"22","author":"Idorn M","year":"2016","unstructured":"Idorn M, Hojman P. Exercise-dependent regulation of NK cells in cancer protection. Trends Mol Med. 2016;22(7):565\u201377.","journal-title":"Trends Mol Med"},{"key":"ref43","article-title":"Exercise-induced \u03b22-adrenergic receptor activation enhances effector lymphocyte mobilization in humans and suppresses lymphoma growth in mice through NK-cells","author":"Baker FL","unstructured":"Baker FL, Agha N, Kunz H et al. Exercise-induced \u03b22-adrenergic receptor activation enhances effector lymphocyte mobilization in humans and suppresses lymphoma growth in mice through NK-cells. Brain Behav Immun 2025;In press.","journal-title":"Brain Behav Immun"},{"issue":"10","key":"ref44","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1158\/2326-6066.CIR-25-0384","article-title":"A dual role for NKG7 in T-cell cytotoxicity and longevity","volume":"13","author":"Wen T","year":"2025","unstructured":"Wen T, Barham W, Dong H. A dual role for NKG7 in T-cell cytotoxicity and longevity. Cancer Immunol Res. 2025;13(10):1510\u20138.","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"ref45","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1517\/14712598.2015.1041912","article-title":"Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies","volume":"15","author":"Rogala B","year":"2015","unstructured":"Rogala B, Freyer CW, Ontiveros EP, Griffiths EA, Wang ES, Wetzler M. Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies. Expert Opin Biol Ther. 2015;15(6):895\u2013908.","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"ref46","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","article-title":"A recombinant bispecific single-chain antibody, CD19\u00d7CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes","volume":"95","author":"L\u00f6ffler A","year":"2000","unstructured":"L\u00f6ffler A, Kufer P, Lutterb\u00fcse R, et al. A recombinant bispecific single-chain antibody, CD19\u00d7CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood. 2000;95(6):2098\u2013103.","journal-title":"Blood"},{"issue":"3\u20134","key":"ref47","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cytogfr.2008.04.003","article-title":"Immune regulation and control of regulatory T cells by OX40 and 4-1BB","volume":"19","author":"So T","year":"2008","unstructured":"So T, Lee SW, Croft M. Immune regulation and control of regulatory T cells by OX40 and 4-1BB. Cytokine Growth Factor Rev. 2008;19(3\u20134):253\u201362.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"3","key":"ref48","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/eji.201445388","article-title":"Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy","volume":"46","author":"Sanchez-Paulete AR","year":"2016","unstructured":"Sanchez-Paulete AR, Labiano S, Rodriguez-Ruiz ME, et al. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy. Eur J Immunol. 2016;46(3):513\u201322.","journal-title":"Eur J Immunol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3389\/fimmu.2017.01211","article-title":"Selection of shared and neoantigen-reactive T cells for adoptive cell therapy based on CD137 separation","volume":"8","author":"Seliktar-Ofir S","year":"2017","unstructured":"Seliktar-Ofir S, Merhavi-Shoham E, Itzhaki O, et al. Selection of shared and neoantigen-reactive T cells for adoptive cell therapy based on CD137 separation. Front Immunol. 2017;8:1211.","journal-title":"Front Immunol"},{"issue":"1","key":"ref50","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1078-0432.CCR-13-0945","article-title":"CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor","volume":"20","author":"Ye Q","year":"2014","unstructured":"Ye Q, Song DG, Poussin M, et al. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res. 2014;20(1):44\u201355.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"ref51","doi-asserted-by":"crossref","first-page":"e1200","DOI":"10.1002\/cti2.1200","article-title":"Ex vivo enrichment of PRAME antigen-specific T cells for adoptive immunotherapy using CD137 activation marker selection","volume":"9","author":"Lee JH","year":"2020","unstructured":"Lee JH, Lee Y, Lee M, et al. Ex vivo enrichment of PRAME antigen-specific T cells for adoptive immunotherapy using CD137 activation marker selection. Clin Transl Immunol. 2020;9(10):e1200.","journal-title":"Clin Transl Immunol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1016\/S2352-3026(25)00144-9","article-title":"Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1\/2 trial","volume":"12","author":"Jabbour E","year":"2025","unstructured":"Jabbour E, Lussana F, Mart\u00ednez-S\u00e1nchez P, Torrent A, Rif\u00f3n JJ, Agrawal V, Tormo M, Cassaday RD, Cluzeau T, Huguet F, Papayannidis C, Hern\u00e1ndez-Rivas JM, Rijneveld A, Fleming S, Vucinic V, B\u00f6ll B, Ikezoe T, Abdul-Hay M, Savoie ML, Schuh AC, et al. Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1\/2 trial. Lancet Haematol. 2025;12:e529\u201341.","journal-title":"Lancet Haematol"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10395685\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10395685\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:17:12Z","timestamp":1794241032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10395685\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":52,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-10395685\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1186\/s12967-026-09042-9","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2026,8,13]]},"subtype":"preprint"}}